Gastroparesis Drugs Market Overview:
The Global Gastroparesis Market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023. Gastroparesis is a medical condition of the stomach, which affects the normal spontaneous movement of the stomach muscles. It restricts the normal digestion, causes vomiting, and problems related with blood sugar levels & nutrition. Various medications or drugs such as reglan, erythromycin, antiemetics, and others are prescribed to treat gastroparesis.
Rise in number of surgeries which lead to postsurgical gastroparesis, increase in diabetic population, growth in geriatric population, and introduction of novel drugs to control symptoms such as nausea and vomiting drive the market. However, the market growth is limited by side effects related to gastroparesis drugs, time-consuming regulatory process for the approval of drugs, and complications in gastroparesis diagnosis. Conversely, surge in demand for the development of user-friendly drugs, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
Gastroparesis Drugs Market Segmentation
The global gastroparesis drugs market is segmented on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market is divided into prokinetic agents, antiemetic agents, and botulinum toxin injections. By disease type, it is classified into diabetic gastroparesis, idiopathic gastroparesis, postsurgical gastroparesis, and others. Depending on distribution channel, it is categorized into hospitals, pharmacies, clinics, and e-commerce. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Idiopathic gastroparesis segment accounted for the largest market share in 2016 and is expected to remain so throughout the forecast period. It is a type gastroparesis, which occurs due to any unknown cause. The symptoms for this type of gastroparesis include nausea, vomiting, early satiety, postprandial fullness, and upper abdominal pain, among which abdominal pain occurs more often. This condition can be managed by dietary modification, prokinetics medications, antiemetic drug therapy, and symptom modulators. Prokinetics medications stimulate gastric motility, antiemetic drug therapy suppresses nausea and vomiting, while symptom modulators such as psychotropic agents reduce symptom expression. Moreover, non-steroidal anti-inflammatory drugs (NSAIDs) may help in controlling the abdominal pain. However, current approved treatment options do not adequately address clinical need; thus, development of new effective therapies for idiopathic gastroparesis is needed.
Gastroparesis Drugs Market, by Disease Type
Snapshot of LAMEA Gastroparesis Drugs Market
Rise in focus of market vendors on emerging markets, namely, Asia-Pacific and LAMEA regions, is expected to boost the market growth. According to IDF 7th Edition, about 29.6 million of the adult population in the South and Central American regions suffered from diabetes in 2015, of which, about 39.0% of them were undiagnosed. Moreover, the estimates of United Nation’s World Population Ageing Report reveal that around 64.4 million people in Africa and 70.9 million people in Latin America and Caribbean belonged to the age group of 60 years and above in 2015. Hence these people are prone to encounter idiopathic or diabetic gastroparesis. Thus, LAMEA offers a huge customer base to the manufacturers of gastroparesis drugs.
Gastroparesis Drugs Market, by Region
There are about 119 clinical trials, including both completed and ongoing trials, in the gastroparesis drugs market. North America accounted for a major share of 61.3%, which constituted to about 73 clinical trials being conducted for gastroparesis drugs, due to the high prevalence of type 1 and type 2 diabetes that led to diabetic gastroparesis.
Europe occupied the second position, accounting for nearly 23 clinical trials performed for gastroparesis drugs, as it has a well-established infrastructure that led to high adoption of gastroparesis drugs.
The Asia-Pacific and LAMEA regions accounted for 18 and 5 clinical trials, respectively, for gastroparesis drugs.
Clinical Trials for Gastroparesis Drugs (%)
The list of key players profiled in this report include Allergan, Plc., Abbott Laboratories (Abbott Arzneimittel GmbH), AstraZeneca Plc., Cadila Pharmaceuticals Ltd., ETX Pharma, Inc, Evoke Pharma, GlaxoSmithKline Plc., Neurogastrx, Inc., Valeant Pharmaceuticals International, Inc., and Theravance Biopharma.
Key players in the value chain include Altos Therapeutics LLC, Mylan N.V., Hexal AG, CEVA Group PLC, and Takeda Pharmaceutical Company Ltd.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the global gastroparesis drugs market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.
- Comprehensive analysis of factors that drive and restrict the market growth is provided.
- Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
Gastroparesis Drugs Market Key Segments:
By Drug Class
- Prokinetic Agents
- Antiemetic Agents
- Botulinum Toxin Injections
By Disease Type
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
By End User
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA